166 related articles for article (PubMed ID: 8360884)
21. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Bhongade BA; Gadad AK
J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
[TBL] [Abstract][Full Text] [Related]
22. Three-dimensional quantitative structure-activity relationships of dioxins and dioxin-like compounds: model validation and Ah receptor characterization.
Waller CL; McKinney JD
Chem Res Toxicol; 1995 Sep; 8(6):847-58. PubMed ID: 7492734
[TBL] [Abstract][Full Text] [Related]
23. Three-dimensional quantitative structure-activity relationship of human immunodeficiency virus (I) protease inhibitors. 2. Predictive power using limited exploration of alternate binding modes.
Oprea TI; Waller CL; Marshall GR
J Med Chem; 1994 Jul; 37(14):2206-15. PubMed ID: 8035428
[TBL] [Abstract][Full Text] [Related]
24. Specific interactions and binding energies between thermolysin and potent inhibitors: molecular simulations based on ab initio molecular orbital method.
Hirakawa T; Fujita S; Ohyama T; Dedachi K; Khan MT; Sylte I; Kurita N
J Mol Graph Model; 2012 Mar; 33():1-11. PubMed ID: 22112671
[TBL] [Abstract][Full Text] [Related]
25. Structural basis for the action of thermolysin.
Tronrud DE; Roderick SL; Matthews BW
Matrix Suppl; 1992; 1():107-11. PubMed ID: 1480010
[TBL] [Abstract][Full Text] [Related]
26. 3D-QSAR CoMFA/CoMSIA models based on theoretical active conformers of HOE/BAY-793 analogs derived from HIV-1 protease inhibitor complexes.
da Cunha EF; Sippl W; de Castro Ramalho T; Ceva Antunes OA; de Alencastro RB; Albuquerque MG
Eur J Med Chem; 2009 Nov; 44(11):4344-52. PubMed ID: 19616874
[TBL] [Abstract][Full Text] [Related]
27. Investigations of Structural Requirements for BRD4 Inhibitors through Ligand- and Structure-Based 3D QSAR Approaches.
Tahir A; Alharthy RD; Naseem S; Mahmood N; Ahmed M; Shahzad K; Akhtar MN; Hameed A; Sadiq I; Nawaz H; Muddassar M
Molecules; 2018 Jun; 23(7):. PubMed ID: 29941841
[TBL] [Abstract][Full Text] [Related]
28. Computational studies on tetrahydropyrimidine-2-one HIV-1 protease inhibitors: improving three-dimensional quantitative structure-activity relationship comparative molecular field analysis models by inclusion of calculated inhibitor- and receptor-based properties.
Nair AC; Jayatilleke P; Wang X; Miertus S; Welsh WJ
J Med Chem; 2002 Feb; 45(4):973-83. PubMed ID: 11831910
[TBL] [Abstract][Full Text] [Related]
29. Comparison of estrogen receptor alpha and beta subtypes based on comparative molecular field analysis (CoMFA).
Xing L; Welsh WJ; Tong W; Perkins R; Sheehan DM
SAR QSAR Environ Res; 1999; 10(2-3):215-37. PubMed ID: 10491851
[TBL] [Abstract][Full Text] [Related]
30. Structure-based alignment and comparative molecular field analysis of acetylcholinesterase inhibitors.
Cho SJ; Garsia ML; Bier J; Tropsha A
J Med Chem; 1996 Dec; 39(26):5064-71. PubMed ID: 8978837
[TBL] [Abstract][Full Text] [Related]
31. Three-dimensional QSAR of HPPD inhibitors, PSA inhibitors, and anxiolytic agents: effect of tautomerism on the CoMFA models.
Zou JW; Luo CC; Zhang HX; Liu HC; Jiang YJ; Yu QS
J Mol Graph Model; 2007 Sep; 26(2):494-504. PubMed ID: 17418602
[TBL] [Abstract][Full Text] [Related]
32. In silico identification of milk antihypertensive di- and tripeptides involved in angiotensin I-converting enzyme inhibitory activity.
Vukic VR; Vukic DV; Milanovic SD; Ilicic MD; Kanuric KG; Johnson MS
Nutr Res; 2017 Oct; 46():22-30. PubMed ID: 29173648
[TBL] [Abstract][Full Text] [Related]
33. 3D-QSAR study on ether and ester analogs of artemisinin with comparative molecular field analysis.
Jiang HL; Chen KX; Wang HW; Tang Y; Chen JZ; Ji RY
Zhongguo Yao Li Xue Bao; 1994 Nov; 15(6):481-7. PubMed ID: 7709742
[TBL] [Abstract][Full Text] [Related]
34. A systematic quantitative approach to rational drug design and discovery of novel human carbonic anhydrase IX inhibitors.
Sethi KK; Verma SM
J Enzyme Inhib Med Chem; 2014 Aug; 29(4):571-81. PubMed ID: 24090419
[TBL] [Abstract][Full Text] [Related]
35. CoMFA modeling of human catechol O-methyltransferase enzyme kinetics.
Sipilä J; Taskinen J
J Chem Inf Comput Sci; 2004; 44(1):97-104. PubMed ID: 14741015
[TBL] [Abstract][Full Text] [Related]
36. CoMFA-based prediction of agonist affinities at recombinant D1 vs D2 dopamine receptors.
Wilcox RE; Tseng T; Brusniak MY; Ginsburg B; Pearlman RS; Teeter M; DuRand C; Starr S; Neve KA
J Med Chem; 1998 Oct; 41(22):4385-99. PubMed ID: 9784114
[TBL] [Abstract][Full Text] [Related]
37. Modeling the cytochrome P450-mediated metabolism of chlorinated volatile organic compounds.
Waller CL; Evans MV; McKinney JD
Drug Metab Dispos; 1996 Feb; 24(2):203-10. PubMed ID: 8742232
[TBL] [Abstract][Full Text] [Related]
38. Quantitative structure-activity relationships/comparative molecular field analysis (QSAR/CoMFA) for receptor-binding properties of halogenated estradiol derivatives.
Gantchev TG; Ali H; van Lier JE
J Med Chem; 1994 Nov; 37(24):4164-76. PubMed ID: 7990116
[TBL] [Abstract][Full Text] [Related]
39. CoMFA modeling of enzyme kinetics: K(m) values for sulfation of diverse phenolic substrates by human catecholamine sulfotransferase SULT1A3.
Sipilä J; Hood AM; Coughtrie MW; Taskinen J
J Chem Inf Comput Sci; 2003; 43(5):1563-9. PubMed ID: 14502490
[TBL] [Abstract][Full Text] [Related]
40. 3D-QSAR comparative molecular field analysis on delta opioid receptor agonist SNC80 and its analogs.
Peng Y; Keenan SM; Zhang Q; Welsh WJ
J Mol Graph Model; 2005 Sep; 24(1):25-33. PubMed ID: 15950508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
